Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 7/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564938 | 0.86 | MAPK13 (0.44) | MAPK13MAPK12MAPK11MAPK14SCD | |
| SCHEMBL5564934 | 0.86 | MAPK13 (0.45) | MAPK13MAPK12MAPK11MAPK14SCD | |
| SCHEMBL27596211 | 0.83 | MAPK14 (0.64) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6876510 | 0.83 | MAPK14 (0.47) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL27615016 | 0.82 | MAPK14 (0.44) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5569283 | 0.82 | SCD (0.46) | MAPK13MAPK12MAPK11MAPK14SCD | |
| SCHEMBL5564819 | 0.81 | MAPK13 (0.44) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6879014 | 0.80 | NPC1 (0.63) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5568773 | 0.79 | NPC1 (0.46) | MAPK13MAPK12MAPK11MAPK14SCD | |
| SCHEMBL5568708 | 0.79 | STK17B (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100363362-C | Thiazole derivatives as NPY receptor antagonists | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | CN | disclosed |
| CN-1639158-A | Thiazole derivatives as NPY receptor antagonists | HOFFMANN LA ROCHE (CH) | 2005-07-13 | — | — | CN | disclosed |